Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Effect of angiotensin converting enzyme inhibitors on the development of chronic subdural haematoma

P. Stejskal, M. Vaverka, S. Trnka, M. Hampl, L. Hrabalek

. 2021 ; 165 (2) : 175-178. [pub] 20200716

Jazyk angličtina Země Česko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22007870

AIMS: Angiotensin converting enzyme inhibitors (ACEI) have been recently discussed in connection with the medical treatment of chronic subdural haematoma (CSDH). They may improve the treatment results. The objective of our study was to evaluate the impact of ACEI on the development of CSDH. The first question was to assess the impact of ACEI on postoperative CSDH healing. The second was to assess the impact of ACEI on the development of CSDH as such. PATIENTS AND METHODS: The study recruited patients treated surgically for CSDH at our department in the 2013-2018 period. Based on medical records, we retrospectively evaluated the clinical condition of the patients, their history (mainly pharmacological - the use of ACEI) and the course of treatment focussing on the reoccurrence of disease necessitating further therapeutic interventions. For the purpose of evaluating the impact of ACEI on postoperative CSDH healing, the patients were divided into two groups: those using ACEI and those without this medication. The results were compared. We also compared the prevalence of ACEI use in patients with CSDH with the prevalence of ACEI in the comparable population. The difference of the rates allowed us to evaluate the impact of ACEI on the development of CSDH itself. RESULTS: Of the 217 patients after surgery for CSDH, 79 continued the use of ACEI; the remaining 138 patients did not use this medication. Patients using ACEI after the surgery experienced a recurrence in 24 (30.4%) cases; patients without ACEI in 37 (26.8%) cases. A negligibly higher number of recurrences was recorded in patients with postoperative use of ACEI, but this difference was not statistically significant (P=0.574). Of a total of 230 patients who underwent surgery for CSDH, 81 were using ACEI chronically (35.2%). In the control group of 100 patients, 38 (38.0%) patients used ACEI. The difference was not statistically significant (P=0.629), so it is not possible to assume that ACEIs influence the development of CSDH as such. CONCLUSION: The initial high hopes for a positive ACEI effect on the healing of CSDH are now waived after the publication of several recent studies. According to our present knowledge, the development of CSDH does not appear to be influenced by ACEI use.

Citace poskytuje Crossref.org

Bibliografie atd.

Literatura

000      
00000naa a2200000 a 4500
001      
bmc22007870
003      
CZ-PrNML
005      
20220330125804.0
007      
ta
008      
220309s2021 xr f 000 0|eng||
009      
AR
024    7_
$a 10.5507/bp.2020.029 $2 doi
035    __
$a (PubMed)32686773
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Stejskal, Přemysl $7 xx0234320 $u Department of Neurosurgery, Faculty of Medicine and Dentistry Palacky University Olomouc and University Hospital Olomouc, Czech Republic
245    10
$a Effect of angiotensin converting enzyme inhibitors on the development of chronic subdural haematoma / $c P. Stejskal, M. Vaverka, S. Trnka, M. Hampl, L. Hrabalek
504    __
$a Literatura
520    9_
$a AIMS: Angiotensin converting enzyme inhibitors (ACEI) have been recently discussed in connection with the medical treatment of chronic subdural haematoma (CSDH). They may improve the treatment results. The objective of our study was to evaluate the impact of ACEI on the development of CSDH. The first question was to assess the impact of ACEI on postoperative CSDH healing. The second was to assess the impact of ACEI on the development of CSDH as such. PATIENTS AND METHODS: The study recruited patients treated surgically for CSDH at our department in the 2013-2018 period. Based on medical records, we retrospectively evaluated the clinical condition of the patients, their history (mainly pharmacological - the use of ACEI) and the course of treatment focussing on the reoccurrence of disease necessitating further therapeutic interventions. For the purpose of evaluating the impact of ACEI on postoperative CSDH healing, the patients were divided into two groups: those using ACEI and those without this medication. The results were compared. We also compared the prevalence of ACEI use in patients with CSDH with the prevalence of ACEI in the comparable population. The difference of the rates allowed us to evaluate the impact of ACEI on the development of CSDH itself. RESULTS: Of the 217 patients after surgery for CSDH, 79 continued the use of ACEI; the remaining 138 patients did not use this medication. Patients using ACEI after the surgery experienced a recurrence in 24 (30.4%) cases; patients without ACEI in 37 (26.8%) cases. A negligibly higher number of recurrences was recorded in patients with postoperative use of ACEI, but this difference was not statistically significant (P=0.574). Of a total of 230 patients who underwent surgery for CSDH, 81 were using ACEI chronically (35.2%). In the control group of 100 patients, 38 (38.0%) patients used ACEI. The difference was not statistically significant (P=0.629), so it is not possible to assume that ACEIs influence the development of CSDH as such. CONCLUSION: The initial high hopes for a positive ACEI effect on the healing of CSDH are now waived after the publication of several recent studies. According to our present knowledge, the development of CSDH does not appear to be influenced by ACEI use.
650    _2
$a inhibitory ACE $x škodlivé účinky $7 D000806
650    _2
$a drenáž $7 D004322
650    12
$a chronický subdurální hematom $x farmakoterapie $x etiologie $7 D020200
650    _2
$a lidé $7 D006801
650    _2
$a recidiva $7 D012008
650    _2
$a retrospektivní studie $7 D012189
655    _2
$a časopisecké články $7 D016428
700    1_
$a Vaverka, Miroslav, $d 1952- $7 skuk0005716 $u Department of Neurosurgery, Faculty of Medicine and Dentistry Palacky University Olomouc and University Hospital Olomouc, Czech Republic
700    1_
$a Trnka, Štefan $7 xx0240181 $u Department of Neurosurgery, Faculty of Medicine and Dentistry Palacky University Olomouc and University Hospital Olomouc, Czech Republic
700    1_
$a Hampl, Martin $7 xx0234317 $u Department of Neurosurgery, Faculty of Medicine and Dentistry Palacky University Olomouc and University Hospital Olomouc, Czech Republic
700    1_
$a Hrabálek, Lumír $7 xx0076898 $u Department of Neurosurgery, Faculty of Medicine and Dentistry Palacky University Olomouc and University Hospital Olomouc, Czech Republic
773    0_
$w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia $x 1213-8118 $g Roč. 165, č. 2 (2021), s. 175-178
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32686773 $y Pubmed
910    __
$a ABA008 $b A 1502 $c 958 $y p $z 0
990    __
$a 20220309 $b ABA008
991    __
$a 20220330125759 $b ABA008
999    __
$a ok $b bmc $g 1775507 $s 1159063
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 165 $c 2 $d 175-178 $e 20200716 $i 1213-8118 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
LZP    __
$b NLK118 $a Pubmed-20220309

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...